|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
FusionGene
|
disease |
ORPHANET |
|
|
|
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
These results reveal a physiological function of cIAP2, identify Bcl10 upregulation as a unifying molecular mechanism for MALT lymphomas, and define the mechanism and effects of this upregulation in t(11;18)-positive MALT lymphomas.
|
16775419 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
These results reveal cIAP2 as an inhibitor of antigenic signaling and implicate its dysfunction in MALT lymphomas.
|
16395405 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
The frequency of API2-MALT1 transcript was lower in thyroid MALT lymphoma(1/12) but similar in pulmonary and gastrointestinal MALT lymphoma.
|
15696476 |
2005 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Genetic alterations underlying the pathogenesis of MALT lymphoma.
|
11960389 |
2002 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment.
|
18216531 |
2008 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
We therefore screened 51 cases of pulmonary MALT lymphoma for API2-MALT1 fusion, and studied its relationship with clinicopathologic factors including the immunohistochemical expression of BCL10, another MALT lymphoma-associated molecule.
|
12651604 |
2003 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Delving deeper into MALT lymphoma biology.
|
16395399 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Taken together, our results strongly indicated that API2-MALT1 possesses a novel mechanism of self-activation by up-regulating its own expression in t(11;18)(q21;q21)-carrying MALT lymphomas, highlighting a positive feedback-loop pathway resulting in unremitting NF-kappaB activation.
|
15982633 |
2005 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
Intestinal MALT lymphomas with API2-MALT1 expression have distinctive forms of infiltration compared with those without translocation.
|
15363040 |
2004 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed the incidence and clinical significance of the MALT lymphoma-associated genetic abnormalities t(11;18)/API2-MALT1, t(1;14)/BCL10-IGH, t(14;18)/IGH-MALT1, t(3;14)/FOXP1-IGH, and extra copies of MALT1 and FOXP1 in gastric MALT lymphomas from Japan.
|
17525089 |
2007 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A possible API2-MLT fusion transcript specific to t(11;18)(q21;q21) was examined by means of reverse transcription-polymerase chain reaction (RT-PCR) in tumours from 47 cases of primary gastrointestinal lymphoma (28 low grade mucosa associated lymphoid tissue (MALT) lymphomas, four low grade MALT lymphomas with a high grade component, nine secondary diffuse large B cell lymphomas, four primary diffuse large B cell lymphomas, and two T cell lymphomas).
|
12499431 |
2003 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In primary pulmonary MALT lymphomas, cytogenetic abnormalities are common (75%) and heterogeneous, encompassing API2-MALT1 and IGH-MALT1, which are mutually exclusive, as well as aneuploidy, which may be present in the latter but is rare in the former.
|
14574335 |
2004 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we examined 14 cases of thymic MALT lymphomas for API2-MALT1 fusion using multiplex reverse transcription polymerase chain reaction and looked for trisomy 3, trisomy 18 and abnormalities of MALT1 and IGH genes using fluorescence in situ hybridization.
|
22243778 |
2012 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The API2-MALT1 fusion oncoprotein is created by the recurrent t(11;18)(q21;q21) chromosomal translocation in mucosa-associated lymphoid tissue (MALT) lymphoma.
|
23770847 |
2014 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most frequently recurring translocations in mucosa-associated lymphoid tissue (MALT) B-cell non-Hodgkin lymphoma, t(11;18)(q21;q21) and t(14;18)(q32; q21), lead to formation of an API2-MALT1 fusion or IgH-mediated MALT1 overexpression.
|
15598810 |
2005 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results reveal cIAP2 as an inhibitor of antigenic signaling and implicate its dysfunction in MALT lymphomas.
|
16395405 |
2006 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This stability of API2-MALT1 may thus result in inappropriate nuclear factor (NF)-kappaB activation, thereby contributing to the pathogenesis of MALT lymphoma.
|
15711920 |
2005 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas.
|
17339192 |
2007 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MALT1, BCL10 (B-cell lymphoma 10), and API2 (apoptosis inhibitor 2)-MALT1 are key molecules in mucosa-associated lymphoid tissue (MALT) lymphomagenesis.
|
16123224 |
2005 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that fusion of MALT1 to API2 mediated by the t(11;18)(q21;q21) may result in an increased inhibition of germinal center B cell apoptosis and subsequent development of MALT lymphomas.
|
11096264 |
2001 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, the c-IAP2/MALT1 fusion protein activates NF-κB by two distinct mechanisms, and loss of c-IAP2 E3 activity in vivo is sufficient to induce abnormalities common to MALT lymphoma.
|
21048983 |
2010 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Successful radiotherapy in a patient with primary rectal mucosa-associated lymphoid tissue lymphoma without the API2-MALT1 fusion gene: a case report and review of the literature.
|
17570523 |
2008 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
BIRC3 inactivation in SMZL recurred because of somatic mutations that disrupted the same RING domain that in extranodal marginal zone lymphoma is removed by the t(11;18) translocation, which points to BIRC3 disruption as a common mechanism across marginal zone B-cell lymphomagenesis.
|
21881048 |
2011 |